Q1 Earnings Forecast for InflaRx Issued By HC Wainwright

Key Points

• HC Wainwright forecasts Q1 2026 EPS of ($0.14) and Q2 EPS of ($0.13), maintaining a "Buy" rating and a $6.00 target on InflaRx, while the market consensus full-year EPS is ($1.04).
• InflaRx reported Q1 EPS of ($0.20), missing the ($0.17) consensus, and recorded revenue of ($0.04) million versus estimates of $0.03 million.
• The stock trades around $0.91 with a $61 million market cap and a 52-week range of $0.71–$1.94; analysts' consensus is a "Moderate Buy" with a $7.50 price target.

InflaRx N.V. (NASDAQ:IFRX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for InflaRx in a research note issued on Thursday, March 19th. HC Wainwright analyst M. Keller anticipates that the company will post earnings of ($0.14) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $6.00 target price on the stock. The consensus estimate for InflaRx's current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx's Q2 2026 earnings at ($0.13) EPS.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of ($0.04) million during the quarter, compared to analyst estimates of $0.03 million.

Other analysts have also recently issued research reports about the stock. Leerink Partners reiterated a "market perform" rating and set a $2.00 target price (down from $5.00) on shares of InflaRx in a research report on Wednesday, December 3rd. Raymond James Financial reaffirmed an "outperform" rating on shares of InflaRx in a research note on Wednesday, December 31st. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of InflaRx in a research note on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

InflaRx Price Performance

Shares of NASDAQ IFRX opened at $0.91 on Friday. InflaRx has a fifty-two week low of $0.71 and a fifty-two week high of $1.94. The firm has a market capitalization of $61.06 million, a P/E ratio of -1.34 and a beta of 1.48. The company's 50 day simple moving average is $0.93 and its 200 day simple moving average is $1.15.

Hedge Funds Weigh In On InflaRx

Several institutional investors and hedge funds have recently modified their holdings of the business. Woodline Partners LP acquired a new stake in InflaRx during the 1st quarter worth approximately $766,000. Squarepoint Ops LLC boosted its holdings in shares of InflaRx by 72.0% in the fourth quarter. Squarepoint Ops LLC now owns 324,349 shares of the company's stock valued at $328,000 after buying an additional 135,826 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of InflaRx during the third quarter worth $214,000. Susquehanna International Group LLP bought a new stake in InflaRx in the 3rd quarter valued at $190,000. Finally, XTX Topco Ltd acquired a new position in InflaRx in the 4th quarter worth $135,000. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.